Figure 6.

Recognition of N-glycans by SARS-CoV-2 RBD. (a) Highest-affinity N-glycan ligands measured by COIN-CaR-nMS. Order number (#) indicates the ranking order. NQ indicates glycan ligand detected but not quantified due to low relative abundance. (b) ACE2⁺ HEK293 cells were treated with kifunensin prior to testing infectivity with a GFP-encoding SARS-CoV-2 pseudotyped virus. %GFP⁺ cells were quantified by flow cytometry. Results are representative of four independent experiments. (c) Infection of ACE2⁺ HEK293 cells treated with kifunensin (or H₂O or remdesivir as controls) with an early clinical isolate of SARS-CoV-2 at 0.1 multiplicity of infection (MOI). Shown is the average viral titers (plaque-forming units (PFUs)) obtained from four biological replicates. Error bars represent 95% CI.